Health Care · Pharmaceutical Preparations

LFCR LIFECORE BIOMEDICAL, INC. DE SEC Filings & Insider Trading Activity 2026

company
CIK 1005286104 filings
Russell 2000

LFCR at a glance

LIFECORE BIOMEDICAL, INC. DE (LFCR, SEC CIK 1005286) filed its latest 10-K annual report on August 7, 2025, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as June 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended May 25, 2025 (FY2025), LIFECORE BIOMEDICAL, INC. DE (LFCR) reported revenue of $128.9 million (up 0.5% from FY2024) and a net loss of $38.7 million. Diluted EPS was -$1.27.
  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding LIFECORE BIOMEDICAL, INC. DE (LFCR) shares worth $39.3 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$128.9M
+0.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
20 funds
$39.3M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $25.3M, down 19% YoY from $31.1M
  • Gross margin 27.0% vs 25.0% YoY, gross profit $6.8M vs $7.8M
  • CDMO largest segment at $17.8M, down 18%; HA manufacturing weakest decline, down 19% to $7.5M
  • Cash $23.0M, operating cash flow $9.5M, revolving facility undrawn with $15.0M available
  • Outlook: liquidity sufficient for at least 12 months, Series A redemption obligation $51.1M due December 28, 2026

Risk Factors

  • New merger risk: closing depends on HSR Act clearance, with the waiting period scheduled to expire November 9, 2026
  • Most material update: Alcon relationship risk, Alcon represented 52% of nine-month revenue and must maintain specified agreements
  • Regulatory risk: additional governmental approval conditions could delay or prevent closing, or impose costs and operating limitations
  • Operational risk: merger uncertainty could disrupt CDMO customer relationships and key personnel retention
  • Financial risk: termination could require a $9,957,716 fee and leave debt maturing May 22, 2029

AI summary of the LFCR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 8.01: Other Events

  • DOJ and FTC early termination of HSR waiting period effective November 4, 2026, clearing the antitrust condition
  • Merger remains pending, with Company stockholder approval and other closing conditions outstanding
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month fiscal 2026 financial results announced for periods ended September 30, 2026
  • Results press release furnished as Exhibit 99.1, providing the substantive financial details

Item EX-99.1: Item EX-99.1

  • Q3 revenue $25.3M, down 18.6%; nine-month revenue $82.7M, down 21.8%, signaling continued demand weakness
  • CDMO revenue fell 18% in Q3 and 29% year-to-date, the primary driver of sales deterioration
Filed Oct 20, 2026Full analysis →

Item 8.01: Other Events

  • Special meeting set for November 4, 2026, to vote on adoption of the merger agreement and proposed merger
  • November 4, 2026 record date determines stockholder voting eligibility

AI summaries of LFCR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LFCR

Don't miss the next LFCR filing

  • Alerts as it files. A push when LFCR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LFCR, by share count.
  • Ask anything. An AI agent that reads every LFCR filing and answers with sources.

LFCR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
OBUS NELSONAJun 4, 2026-
Kiper Christopher SAJun 4, 2026-
Antunes Humberto CalheirosAJun 4, 2026-
Johnson Paul HaroldAJun 4, 2026-
Korenberg Matthew EAJun 4, 2026-
Schechter JoshuaAJun 4, 2026-
HOUDE LOVAS KATRINAAJun 4, 2026-
Aryeh JasonAJun 4, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$128.3M$128.9M
Gross Profit-$41.9M$40.3M
Operating Income--$8.8M-$17.2M
Net Income-$12.0M-$38.7M
Gross Margin-32.6%31.3%
Op. Margin--6.9%-13.4%
Net Margin-9.4%-30.0%
Balance Sheet
Total Assets$253.5M$254.0M$239.3M
Equity-$11.3M$1.3M
ROE-106.2%-2898.0%
Per Share
EPS$-3.32$0.32$-1.27
Cash Flow
Operating CF--$217K-$206K
CapEx-$18.4M$13.4M

Source: XBRL data in LIFECORE BIOMEDICAL, INC. DE (LFCR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LFCR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LFCR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$39.3M
Q2 202621$31.0M
Q1 202619$20.4M
Q4 202521$47.6M
Q3 202519$39.7M
Q2 202520$46.2M
Q1 202516$23.2M
Q4 202411$20.8M
Position changes: Q2 2026 → Q3 2026
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 147 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LFCR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 5, 2026Analysis-
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 20, 2026Analysis-
8-KSep 29, 2026Analysis-
8-KSep 28, 2026Analysis-
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
SC 13GJul 29, 2026-
8-KJul 2, 2026Analysis-
4Jun 8, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
8-KJun 5, 2026Analysis
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4May 21, 2026-
8-KMay 6, 2026Analysis
10-QMay 6, 2026Analysis
4Apr 16, 2026--
8-KMar 16, 2026Analysis-
8-KMar 5, 2026Analysis-

Related Health Care companies

All Health Care →

LFCR SEC filings: frequently asked questions

Which institutions hold LFCR stock?

As of September 30, 2026, the largest LIFECORE BIOMEDICAL, INC. DE (LFCR) holders among the 13F filers tracked by SignalX were BlackRock ($13.3 million), Vanguard Capital Management LLC ($8.5 million), Morgan Stanley ($4.9 million), State Street Corp ($4.2 million), Citadel Advisors LLC ($1.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LFCR's revenue in fiscal year 2025?

For the fiscal year ended May 25, 2025 (FY2025), LIFECORE BIOMEDICAL, INC. DE (LFCR) reported revenue of $128.9 million (up 0.5% from FY2024) and a net loss of $38.7 million. Diluted EPS was -$1.27. The figures come from the XBRL data in the 10-K.

What did LFCR report in its latest 8-K?

LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K on November 5, 2026 reporting Item 8.01 (Other Events). DOJ and FTC early termination of HSR waiting period effective November 4, 2026, clearing the antitrust condition.

What are the latest LFCR SEC filings?

LIFECORE BIOMEDICAL, INC. DE (LFCR) filed its latest 10-K annual report on August 7, 2025, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on June 8, 2026.

What is LFCR's SEC CIK number?

LIFECORE BIOMEDICAL, INC. DE (LFCR)'s SEC Central Index Key (CIK) is 1005286. EDGAR lists every LFCR filing under that number.

Ask anything about LFCR

The research agent reads LFCR's filings, financials, insider trades and 13F holders, then answers with sources.